Comparative remission rates of schizophrenic patients using various remission criteria

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 7, 2008, Pages 1643-1651

  Beitinger, Romain ^a   Lin, Jingxia ^a   Kissling, Werner ^a   Leucht, Stefan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antipsychotic drugs; Remission; Response; Schizophrenia

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE; ZIPRASIDONE;

ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; HEBEPHRENIA; HUMAN; LOW DRUG DOSE; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; STATISTICAL ANALYSIS; TREATMENT DURATION;

ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; DATABASES, FACTUAL; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 51349083547     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.06.008     Document Type: Article

References (32)

1. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, Third Revision, Revised (DSM-III-R) (1987), American Psychiatric Association, Washington, DC
2. American Psychiatric Association. Diagnostic and Statistical Manual For Mental Disorders, Fourth Edition (1994), American Psychiatric Association, Washington, DC
3. Andreasen N., Carpenter W., Kane J., Lasser R., Marder S., and Weinberger D. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry 62 (2005) 441-449
4. Beasley C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., and Beuzen J.-N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 7 (1997) 125-137
5. Beasley C.M., Sanger T., and Satterlee W. Olanzapine versus placebo: results of a double-blind fixed dose olanzapine trial. Psychopharmacology 124 (1996) 159-167
6. Breier A., Berg P., Thakore J., Naber D., Gattaz W.F., Cavazzoni P., Walker D.J., Roychowdhury S.M., and Kane J. Olanzapine versus ziprasidone: results of the 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 162 10 (2005) 1879-1887
7. Buckley P.F., Harvey P.D., Bowie C.R., and Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 94 (2007) 99-106
8. De Hert M., van Winkel R., Wampers M., Kane J., van Os J., and Peuskens J. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 92 (2007) 68-73
9. Emsley R., Rabinowitz J., and Medori R. Remission in early psychosis: rates, predictors, and clinical and functional outcome correlates. Schizophr Res 89 (2007) 129-139
10. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology, Revised (DHEW Publ No ADM 76-338) (1976), National Institute of Mental Health, Rockville, MD, 218-222
11. Helldin L., Kane J.M., Karilampi U., Norlander T., and Archer T. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiatr Res 40 (2006) 738-745
12. Helldin L., Kane J.M., Karilampi U., Norlander T., and Archer T. Remission in prognosis of functional outcome: a new dimension in the treatment of patients with psychotic disorders. Schizophr Res 93 (2007) 160-168
13. Jager M., Riedel M., Schmauss M., Laux G., Pfeiffer H., Naber D., et al. Prediction of symptom remission in schizophrenia during inpatient treatment. World J Biol Psychiatry (2007) 1-9
14. Kane J.M., Crandall D.T., Marcus R.N., Eudicone J., Pikalov III A., Carson W.H., and Swyzen W. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 95 (2007) 143-150
15. Kane J.M., Honigfeld G., Singer J., and Meltzer H. Clozaril Collaborative study group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Psychopharmacol Bull 24 1 (1988) 62-67
16. Kane J.M., Leucht S., Carpenter D., and Docherty J.P. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 64 Suppl 12 (2003) 5-19
17. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-275
18. Leucht S., and Kane J.M. Measurement based psychiatry in schizophrenia: definitions of response, remission, stability and relapse. J Clin Psychiatry 67 11 (2006) 1813-1814
19. Leucht S., Kane J.M., Kissling W., Hamann J., Etschel E., and Engel R.R. Clinical implications of BPRS scores. Br J Psychiatry 187 1 (2005) 62-67
20. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM, in press-a. How effective are second generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Molecular Psychiatry. [advance online publication, 2008 Jan 8].
21. Leucht S., Beitinger R., and Kissling W. On the concept of remission in schizophrenia. Psychopharmacology (Berl). 194 4 (2007) 453-461
22. Leucht S., Engel R.R., Kane J.M., and Davis J.M. Defining 'response' in antipsychotic drug trials: recommendations for the use of scale derived cutoffs. Neuropsychopharmacology 32 9 (2007) 1903-1910
23. Lieberman J.A., Tollefson G., Tohen M., Green A.I., Gur R.E., Kahn R., et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry 160 (2003) 1396-1404
24. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 12 (2005) 1209-1223
25. LMcIntyre R.S., Fallu A., and Konarski J.Z. Measurable outcomes in psychiatric disorders: remission as a marker of wellness. Clin Ther 28 (2006) 1882-1891
26. Novick D., Haro J.M., Suarez D., Lambert M., Lepine J.P., and Naber D. Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study. Psychopharmacology (Berl) 191 (2007) 1015-1022
27. Opler M.G., Yang L.H., Caleo S., and Alberti P. Statistical validation of the criteria for symptom remission in schizophrenia: preliminary findings. BMC Psychiatry 7 (2007) 35
28. Peuskens J., Kaufman L., and Van Vleymen B. Analysis of resolution criteria in patients with schizophrenia treated with olanzapine for an acute psychotic episode. Schizophr Res 95 (2007) 169-173
29. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154 (1997) 457-465
30. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17 (1997) 407-418
31. van Os J., Burns T., Cavallaro R., Leucht S., Peuskens J., Helldin L., et al. Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica 113 (2006) 91-95
32. Wahlbeck K., Tuunainen A., Ahokas A., and Leucht S. Drop-out rates in randomised antipsychotic drug trials. Psychopharmacology (Berl) 155 3 (2001) 230-233